Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Retatrutide phase 2 (obesity)

Retatrutide phase 2 (obesity)

Retatrutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Retatrutide
Population
obesity
Phase
2
Participants
338
Duration
48 weeks
Registry
NCT04881760

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
retatrutide 12 mgobesity48338−24.2 % vs −2.1 %
Δ −22.1 pp
——16.0 vs 0.0—45.0 vs 11.019.0 vs 1.03.0 vs 4.0—verified
retatrutide 8 mg (start 4 mg)obesity48338−23.9 % vs −2.1 %
Δ −21.8 pp
——6.0 vs 0.0—60.0 vs 11.026.0 vs 1.06.0 vs 4.0—verified
retatrutide 4 mg (start 4 mg)obesity48338−17.8 % vs −2.1 %
Δ −15.7 pp
——9.0 vs 0.0—36.0 vs 11.012.0 vs 1.06.0 vs 4.0—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (15)
  • retatrutide 12 mg · ae_dc · Table 3, AEs leading to discontinuation
    Any event 0 5 (7) 2 (6) 3 (9) 5 (14) 2 (6) 10 (16) 27 (8)
  • retatrutide 12 mg · nausea · Table 3
    Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
  • retatrutide 12 mg · vomiting · Table 3
    Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
  • retatrutide 12 mg · sae · Table 3
    Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
  • retatrutide 12 mg · weight_eff · Results, Changes in Body Weight
    −24.2% in the 12-mg group with an initial dose of 2 mg
  • retatrutide 8 mg (start 4 mg) · ae_dc · Table 3
    8 mg (initial 4 mg): 2 (6%)
  • retatrutide 8 mg (start 4 mg) · nausea · Table 3
    Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
  • retatrutide 8 mg (start 4 mg) · vomiting · Table 3
    Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
  • retatrutide 8 mg (start 4 mg) · sae · Table 3
    Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
  • retatrutide 8 mg (start 4 mg) · weight_eff · Results, Changes in Body Weight
    −23.9% in the 8-mg group (initial dose 4 mg)
  • retatrutide 4 mg (start 4 mg) · ae_dc · Table 3
    4 mg (initial 4 mg): 3 (9%)
  • retatrutide 4 mg (start 4 mg) · nausea · Table 3
    Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
  • retatrutide 4 mg (start 4 mg) · vomiting · Table 3
    Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
  • retatrutide 4 mg (start 4 mg) · sae · Table 3
    Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
  • retatrutide 4 mg (start 4 mg) · weight_eff · Results, Changes in Body Weight
    −17.8% in the 4-mg group with an initial dose of 4 mg

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Retatrutide phase 2 (obesity). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/retatrutide-phase-2-obesity/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.